Investors advised to avoid Teladoc Health and Tandem Diabetes Care due to challenges and risk

From Yahoo Finance: 2025-04-12 14:05:00

Investors are taking advantage of market dips caused by Trump’s tariffs to purchase shares of top companies. However, it’s crucial to avoid investing in companies like Teladoc Health and Tandem Diabetes Care, which are facing challenges. Teladoc Health, a telemedicine specialist, has seen declining revenue growth and struggles to turn a profit despite high growth margins. Tandem Diabetes Care, known for its innovative insulin pumps, has faced economic troubles, competition, and struggles with profitability. Trump’s tariffs could further impact these companies negatively, making them risky investments at this time.

Teladoc Health is working on growth opportunities and artificial intelligence initiatives, but its poor recent results and lack of profitability make it a risky stock to invest in. Tandem Diabetes Care, despite its innovative attributes, faces bleak prospects due to economic challenges and competition. It’s best to avoid investing in these companies for now.



Read more at Yahoo Finance: 2 Beaten-Down Stocks to Avoid in the Tariff-Fueled Correction